Sigma Pharmaceuticals Limited (ASX:SIP) has rebounded from an interim net loss last year to a net profit of $26.65 million in the first half of fiscal 2012.
The drug manufacturer says the result was driven by improved operating performance and lower interest costs.
Over the first six months of this year earnings before interest and tax increased 55 per cent, reflecting growth in underlying sales.
Total revenue fell 2.4 per cent, due to the impact of the withdrawal of Pfizer Australia products.
Looking ahead Sigma has cautioned the year will be impacted by the ongoing impact of the federal government's pharmaceutical benefits scheme reforms.
Sigma has declared a fully franked interim dividend of 1.5 cents per share.
In the 2011 financial year Sigma Pharmaceuticals nearly halved its full year net loss to $235 million.
